Basal Ganglia Diseases, Biomarkers, Central Nervous System Diseases, Cognitive Impairment, Gait Analysis, Gait Disorders, Neurologic, Magnetic Resonance Imaging, Movement Disorders, Neurodegenerative Diseases, Parkinson Disease, Parkinsonian Disorders, Pathologic Processes, Physiotherapy, Rehabilitation Outcome, Synucleinopathies
Conditions
Brief summary
Parkinson's disease (PD) is a progressive neurological disorder characterized by motor and non-motor symptoms such as rigidity, bradykinesia, resting tremor, cognitive and autonomic dysfunctions, gait and balance difficulties. The impairment of gait, balance and cognitive performances is partially responsive to dopaminergic medications. This emphasizes the importance of non-pharmacological interventions for people with PD (pwPD). Intensive multidisciplinary motor and cognitive rehabilitation has been proposed as a complementary and effective treatment for managing pwPD. Several structural and physiological mechanisms have been suggested to underpin exercise-induced neuroplastic changes in PD, such as enhanced synaptic strength and preservation of dopamine neurons. To date, studies on brain changes induced by motor and cognitive exercises in pwPD have been small-scaled and uncontrolled. Identifying accessible and measurable biomarkers for monitoring the events induced by intensive motor and cognitive rehabilitation program would help in testing the treatment effectiveness and would allow personalization of rehabilitation strategies by predicting patients' responsiveness. Based on validated clinical assessments of intensive multidisciplinary rehabilitation treatment, the project will test the ability of a new set of biomarkers to evaluate rehabilitative outcomes in a cohort of people with PD.
Detailed description
While pharmacological treatment is helpful in the early stages of the disease, increased attention has been given to rehabilitation that may lead to clinical improvements in motor and non-motor impairments. Recently synthesized evidence suggests that physical exercise may lead to neuroplastic changes at the functional, structural and molecular levels. Accessible and measurable biomarkers are needed to monitor the disease progression and the neurobiological changes resulting from pharmacological and rehabilitative treatments, also can be a useful and valuable tool to test rehabilitation effectiveness. The present project will start from the reliable clinical assessment of rehabilitation effectiveness of an intensive multidisciplinary rehabilitation program, to verify the ability of a new panel of measurable biomarkers to assess neurobiological and functional changes in pwPD. The purpose of this study is to determine the effects of an intensive multidisciplinary, aerobic, motor-cognitive rehabilitation treatment on accessible and measurable molecular biomarkers (primary outcome); balance and gait performance; aerobic capacity; motor and non-motor symptoms; cognitive functions; neuroimaging biomarker (secondary outcomes) in comparison to an active control group receiving a home-based self-treatment program. Thereafter, the investigators aim to relate the effects seen in motor and non-motor behavior to changes in biomolecular and neuroimaging markers. To achieve this purpose, the study is designed as a Randomized Controlled Trial (RCT) and participants will be recruited at Fondazione Don C. Gnocchi-ONLUS, IRCCS S. Maria Nascente. Seventy-two subjects with a diagnosis of PD in accordance of MDS criteria will be randomly allocated to the experimental (EXP) or control group (CTR).
Interventions
BEHAVIORALMultidisciplinary Intensive Rehabilitation
The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs. The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks. The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim).
BEHAVIORALMuscle-stretching and active mobilization exercises
The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
Sponsors
Fondazione Don Carlo Gnocchi Onlus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Intervention model description
This study is designed as a Randomized Controlled Trial (RCT). Subjects with a diagnosis of PD in accordance of MDS criteria will be randomly allocated to the experimental (EXP) or control group (CTR). Clinical, kinematic, blood samples and MRI data will be collected before (T0) at the end of treatment (T1) and 3 months after the end of treatment (T2).
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* PD diagnosis according to MDS Criteria (MDS clinical diagnostic criteria for Parkinson's disease, Postuma et al., 2015); * Modified Hoehn&Yahr (H&Y): stages from 1.5 to- 3; * Stable pharmacological treatment in the last 4 weeks.
Exclusion criteria
* Vascular, familiar and drug- induced forms of parkinsonism, other known or suspected causes of parkinsonism (metabolic, brain tumor etc) or any suggestive features of atypical parkinsonism; * Significant comorbidities and/or severe systemic diseases that would preclude exercise participation (eg.recent surgery, unstable cardiac dysfunction, anemia, hepatosis, pulmonary disorders, chronic renal failure; auditory, visual and/or vestibular dysfunctions, presence of DBS); previously diagnosed psychiatric diseases. * Dementia as defined by Montreal Cognitive Assessment (MoCA Test) Correct Score\<15.51 (Santangelo et al., 2014); * Rehabilitation treatment in the previous 4 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum biomarkers in neuron derived extracellular vesicles (NDEVs) | 18 weeks | Oligomeric α-synuclein (α-syn) ng/ml; SNARE complex: Syntaxyn-1(STX-1A) (ng/ml), VAMP-2 (ng/ml) and SNAP-25 (ng/ml); Brain-Derived Neurotrophic Factor (BDNF) (ng/ml), pro-BDNF (ng/ml), Glial cell line-derived Neurotrophic factor (GDNF) (ng/ml) Cerebral dopamine neurotrophic factor (CDNF) (ng/ml) |
| Blood Biomarkers | 18 weeks | Pro- \[IL-1β (pg/ml), Tumour Necrosis Factor alpha (TNFα) (pg/ml), Interferon gamma (IFN-γ) (pg/ml), IL-6 (pg/ml), IL-18 (pg/ml)\], Anti-inflammatory (IL-10) (pg/ml) cytokines. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gait speed | 18 weeks | 10 Meter Walk Test (10MWT) assess walking speed in meters per second over a distance of 6 meters. |
| Strenght | 18 weeks | 5-Time Sit-To-Stand (5TSTS) is based on the amount of time (in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. |
| Balance | 18 weeks | Modified Dynamic Gait Index (mDGI): The mDGI measure balance skills consists of 8 items and results in a total score of 0 to 64. |
| Gait Analysis | 18 weeks | Gait analysis will be assessed using a 9-camera SMART-D motion capture system (BTS, Milano, Italy) in order to measure stride length, step width and length, kinematic data and energy recovery. |
| Motor and non-motor symptoms | 18 weeks | The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I-IV. MDS-UPDRS-PART I ''nonmotor experiences of daily living -nM-EDL- range: 0-52, 0=better outcome, 52=worse outcome; PART-II ''motor experiences of daily living -M-EDL-'' range: 0-52, 0=better outcome, 52=worse outcome; PART-III ''motor examination'' range: 0-132, 0=better outcome, 132=worse outcome; PART IV ''motor complications'' range: 0-24, 0=better outcome, 24=worse outcome. |
| Non-Motor symptoms | 18 weeks | Non-Motor Symptoms Scale (NMSS) \[range: 0-360, 0=better outcome, 360=worse outcome\]; |
| Fatigue | 18 weeks | Parkinson Fatigue Scale (PFS) \[range: 1-5, 1=better outcome, 5=worse outcome\]; |
| Daytime sleepiness | 18 weeks | Epworth Sleepiness Scale (ESS) \[range: 0-24, 0=better outcome, 24=worse outcome\]; |
| Sleep quality | 18 weeks | Pittsburgh Sleep Quality Index (PSQI) \[range: 0-21, 0=better outcome, 21=worse outcome\]; |
| Rapid eye movement sleep behavior disorder | 18 weeks | REM sleep behavior disorder screening questionnaire (RBDSQ) \[range: 0-13, 0=better outcome, 13=worse outcome\]. |
| Autonomic Symptoms | 18 weeks | Italian version of the Composite Autonomic Symptoms Score (COMPASS-31) \[weighted score range: 0-100, 0=better outcome, 100=worse outcome\]; |
| Pain Intensity | 18 weeks | Numeric Rating Scale (NRS) \[range: 0-10, 0=better outcome, 10=worse outcome\]; |
| Parkinson's disease-specific health related quality of life | 18 weeks | The Parkinson Disease Questionnaire (PDQ-39) \[PDQ-39 range: 0%-100%; 0%=better outcome, 100%=worse outcome\]. |
| Global Cognitive Functioning | 18 weeks | Montreal Cognitive Assessment (MoCA Test)\[0-30, 0=worse, 30=better outcome\] and Mini-Mental Parkinson (MMP)\[0-32, 0=worse, 32=better outcome\] |
| Verbal short-term and working memory | 18 weeks | Forward and Backward Verbal Span \[0-9, 0=worse, 9=better outcome\] |
| Verbal episodic memory | 18 weeks | Immediate and delayed story recall test \[0-8, 0=worse, 8=better outcome; Oblivion Index range: 0-8, 0=worse, 8=better outcome\] |
| Visuo-constructional ability | 18 weeks | Rey's Figure - Copy \[0-36, 0=worse, 36=better outcome\] |
| Visuo-spatial memory | 18 weeks | Rey's Figure - Recall \[0-36, 0=worse, 36=better outcome\] |
| Frontal lobe functioning | 18 weeks | Frontal Assessment Battery (FAB) \[0-18, 0=worse, 18=better outcome\] |
| Non-verbal reasoning | 18 weeks | Raven Coloured Progressive Matrices (CPM-47) \[0-36, 0=worse, 36=better outcome\] |
| Extradimensional verbal set-shifting | 18 weeks | Alternate Verbal Fluency \[0-∞, 0=worse, ∞=better outcome;Shifting Index 0-1, 0=worse, 1=better outcome\] |
| Extradimensional non-verbal set-shifting | 18 weeks | Trail Making Test (TMT) \[0-∞, 0=worse, ∞=better outcome\] |
| Speed information processing | 18 weeks | Symbol Digit Modalities Test (SDMT) (Oral Version) \[0-120, 0=worse, 120=better outcome\] |
| Cognitive interference inhibition | 18 weeks | Stroop Test-Short Version \[Error: 0-30, 0=better, 30=worse outcome;Time: range: 0-∞, 0=better, ∞=worse outcome\] |
| IdeoMotor praxis | 18 weeks | Gesture Imitation Test (IMA-T) \[0-72, 0=worse, 72=better outcome\] |
| Language production and non-motor processing speed | 18 weeks | Verbal fluency test (phonemic and semantic tasks) \[0-∞, 0=worse, ∞=better outcome\] |
| Depression | 18 weeks | Beck Depression Inventory-II (BDI-II) \[0-63, 0=better, 63=worse outcome\] |
| Anxiety | 18 weeks | State-Trait Anxiety Inventory. Forma Y (STAI-Y) \[20-80; STAI-Y TRAIT ANXIETY range: 20-80; 20=better, 80=worse outcome\] |
| Apathy | 18 weeks | Dimensional Apathy Scale (I-DAS) \[0-72, 0=better, 72=worse outcome\] |
| Anhedonia | 18 weeks | Snaith-Hamilton Pleasure Scale (SHAPS) \[0-14, 0=better, 14=worse outcome\] |
| Impulsivity | 18 weeks | Barratt Impulsiveness Scale-11 (BIS-11) \[30-120, ;30=better, 120=worse outcome\] |
| Alexithymia | 18 weeks | Toronto Alexithymia Scale (TAS-20) \[20-100, 20=better, 100=worse outcome\] |
| Impulsive Control Disorders | 18 weeks | Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP-RS-IT) \[0-112,; 0=better, 112=worse outcome\] |
| Behavioral disturbances | 18 weeks | NeuroPsychiatric Inventory Questionnaire (NPI-Q) \[SE: 0-36, 0=better, 36=worse outcome; ST= 0-60, 0=better, 60=worse outcome\] |
| Functional disability | 18 weeks | Modified Barthel Index (MBI) \[range: 0-100, 0=worse outcome, 100=better outcome\]; |
| Daily self-care activities | 18 weeks | Activities of Daily Living (ADL) \[0-6, 0=worse, 6=better outcome\] Instrumental Activities Of Daily Living (IADL) \[0-8, 0=worse, 8=better outcome\] |
| Dynamic Balance | 18 weeks | \- Timed-Up and -Go Test (TUG); subjects are asked to rise from a standard armchair, walk to a marker 3 m away, turn, walk back, and sit down again. The Time (seconds) is measured. |
| Brain functional connectivity | 18 weeks | Advanced Magnetic Resonance Imaging (MRI)-3 Tesla protocols, including resting state functional MRI to assess the neural correlates of rehabilitation-induced brain plasticity in pwPD undergoing intensive motor and cognitive rehabilitation. |
| Cerebral blood flow | 18 weeks | Advanced MRI-3 Tesla protocols, including arterial spin labeling (ASL) to assess the neural correlates of rehabilitation-induced brain plasticity in pwPD undergoing intensive motor and cognitive rehabilitation. |
| Home-based motor activity monitoring | 18 weeks | The acquisitions will be obtained from the actigraphs (mounted one on the right wrist and the other on the left wrist). |
| Caregiver burden | 18 weeks | Caregiver Burden Inventory (CBI) \[range 0-96, 0=better, 96=worse outcome\] |
| Aerobic capacity and endurance | 18 weeks | 6 Minute Walk Test (6-MWT). The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. |
Countries
Italy
Contacts
Primary ContactMario Meloni, MD; PhD
Outcome results
None listed